Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate… read more.
Mallinckrodt Plc announced that the Cardiovascular And Renal Drugs Advisory Committee of the U.S. FDA voted to recommend approval for its investigational agent terlipressin to treat adults with… read more.
The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study (AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.
The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. and Biogen Inc., announced that a new Phase III clinical study ?AHEAD 3-45) of BAN 2401, an antiamyloid beta… read more.
Ovid Therapeutics Inc. and Angelini Pharma S.p.A. announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV 101 (gaboxadol) for the potential… read more.
Genentech, a member of the Roche Group announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did… read more.
Equillium, Inc., announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized… read more.
Alnylam Pharmaceuticals, announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria… read more.
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published… read more.
Idorsia Ltd announced positive top-line results of the second pivotal Phase III study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant , in… read more.
Atox Bio announced results from the randomized, double-blind, placebo-controlled Phase III ACCUTE (AB103 Clinical Composite endpoint StUdy in Necrotizing Soft Tissue infEctions) trial of reltecimod for the early… read more.
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
